Cancer Guidelines Database

Access quality cancer guidelines from a single Canadian source

We've listed guidelines under your selection of "Type of cancer". The most recent guidelines are first.

British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines for the Management of Primary Cutaneous Lymphomas 2018

Year: 2018
AGREE II score: Available
Developer organization: British Association of Dermatologists
This is a clinical practice guideline for the management of adult patients with primary cutaneous B-cell and T-cell lymphomas. This guideline does not include patients presenting with or found to have skin involvement as part of a systemic lymphoma. Treatment recommendations are organized by clinicopathological subtypes of lymphomas and are further stratified based on the stage of the disease. Economic and practical considerations of also discussed.

An Update on the Society for Immunotherapy of Cancer Consensus Statement on Tumor Immunotherapy for the Treatment of Cutaneous Melanoma: Version 2.0

Year: 2018
AGREE II score: Available
Developer organization: Society for Immunotherapy of Cancer
This is a clinical practice guideline for patients with cutaneous melanoma. The guideline examines the immunotherapy options for the treatment of this patient population. Topics of interest include the different immunotherapy options for every stage of melanoma and special issues in tumour immunotherapy.

French Updated Recommendations in Stage I to III Melanoma Treatment and Management

Year: 2017
AGREE II score: Unavailable
Developer organization: French Dermatological Society
This is a clinical practice guideline for the management of stage I to III melanoma in adult patients. The guideline discusses classification, resection margins, sentinel node biopsy, adjuvant treatments, initial work-up, follow-up, and the role of molecular biology tests. The guideline also compares the recommendations provided by other European guidelines and addresses any disparities in recommendations.

Guidelines of Care for the Management of Primary Cutaneous Melanoma

Year: 2019
AGREE II score: Available
Developer organization: American Academy of Dermatology
This is a clinical practice guideline for patients with primary cutaneous melanoma. The guideline provides treatment recommendations for this patient population, including recommendations for surgical margins. Specific topics discussed include biopsy techniques for lesions that are clinically suggestive of melanoma, histopathologic interpretation of cutaneous melanoma, the use of laboratory, molecular, and imaging tests during initial work-up or follow-up, as well as the concept of staged excision.

Management of Cutaneous Squamous Cell Carcinoma in Patients With Epidermolysis Bullosa: Best Clinical Practice Guidelines

Year: 2015
AGREE II score: Unavailable
Developer organization: British Association of Dermatologists
This is a clinical practice guideline for patients with epidermolysis bullosa. The guideline provides recommendations for the diagnosis, staging, and management of cutaneous squamous cell carcinoma (SCC) in these patients. Specific topics discussed include surveillance and diagnosis, tumour evaluation and staging, surgical treatment, nonsurgical treatment, the use of prosthetics, and end-of-life care.

Indication Guidelines for Mohs Micrographic Surgery in Skin Tumors

Year: 2015
AGREE II score: Unavailable
Developer organization: Brazilian Society of Dermatology
This is a clinical practice guideline for patients with skin tumours. The guideline examines the indications for Mohs micrographic surgery in these patients. Indications related to recurrence, histology, size, definition of tumour margins, and tumour location are discussed. The use of Mohs micrographic surgery for treating different types of skin tumours is compared to conventional surgery in the appropriate situations.

Consensus Recommendations for Management of Malignant Melanoma

Year: 2016
AGREE II score: Unavailable
Developer organization: Cancer Care Manitoba
This is a clinical practice guideline for the management of malignant melanoma. Topics of interest include acceptable time intervals from referral to surgical management, which patients should be candidates for sentinel lymph node biopsy, and acceptable surgical margins.

Cutaneous Melanoma: A National Clinical Guideline

Year: 2017
AGREE II score: Available
Developer organization: Scottish Intercollegiate Guidelines Network
This is a clinical practice guideline for patients with cutaneous melanoma. The guideline examines the care of these patients throughout the cancer care continuum, including prevention and surveillance, diagnosis and prognosis, surgical management and staging, further investigations and non-surgical staging, adjuvant treatment of stage 2 and 3 melanoma, follow up of patients with stage 1, 2 and 3 melanoma, and management of advanced (unresectable stage 4 or 5) melanoma.

Primary Cutaneous Lymphomas, Version 2.2019

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
A clinical practice guideline on the diagnosis, workup, and treatment of patients who have been diagnosed with or are suspected of having primary cutaneous B-cell lymphomas (PCBCLs). The guideline focuses on the three main types of PCBCLs: primary cutaneous marginal zone lymphoma (PCMZL), primary cutaneous follicle-center lymphoma (PCFCL), and primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, leg type). Recommendations for treatment are provided based on lymphoma type and whether treatment is for initial, relapsed, or refractory disease.

Merkel Cell Carcinoma, Version 1.2019

Year: 2018
AGREE II score: Available
Developer organization: National Comprehensive Cancer Network
This is a clinical practice guideline for patients with Merkel cell carcinoma. The guideline provides recommendations on diagnosis, workup, staging, radiation therapy, chemotherapy, follow-up, and recurrence. Specific recommendations are provided for the postoperative management of primary tumours, management of the draining nodal basin, and treatment of distant metastatic disease.